Edition:
United States

AnGes Inc (4563.T)

4563.T on Tokyo Stock Exchange

580JPY
1:13am EDT
Change (% chg)

¥-24 (-3.97%)
Prev Close
¥604
Open
¥594
Day's High
¥595
Day's Low
¥570
Volume
2,209,100
Avg. Vol
9,285,924
52-wk High
¥884
52-wk Low
¥214

Chart for

About

AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of... (more)
No analyst recommendations are available for .

Overall

Beta: 1.59
Market Cap(Mil.): ¥49,537.57
Shares Outstanding(Mil.): 78.63
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 91.81 16.83
EPS (TTM): -- -- --
ROI: -- 2.42 10.92
ROE: -- 3.28 14.52

BRIEF-AnGes submits CTN of hypertension DNA vaccine

* Says it submitted Clinical Trial Notification (CTN) of hypertension DNA vaccine to Therapeutic Goods Administration (TGA) in Australia

Jul 19 2017

BRIEF-Anges MG says exercise of options

* Says 20,000 units of its 29th series options were exercised to 2 million shares of its common stock from June 10 to June 12

Jun 12 2017

BRIEF-Anges expects to apply for approval to manufacture treatment for severe blockage of the arteries in the legs - nikkei

* Anges expects to apply in October for approval to manufacture and market treatment for severe blockage of the arteries in the legs - Nikkei Further company coverage:

Jun 09 2017

BRIEF- Anges MG announces exercise of options through private placement

* Says 12,500 units of its 29th series options were exercised to 1.3 million shares of its common stock from June 1 to June 9, through private placement

Jun 09 2017

BRIEF- Anges MG announces exercise of options

* Says 8,500 units of its 29th series options were exercised to 850,000 shares of its common stock from May 24 to May 31, through private placement

May 31 2017

BRIEF-Anges MG receives IND approval from FDA

* Says it received investigational new drug (IND) approval from FDA, for a clinical trial with F-kappaB decoy oligo DNA in U.S, for treatment of discogenic lower back pain

Apr 24 2017

Earnings vs. Estimates